Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences

14-02-2024 | Platelet Transfusion | Original Article

A multicenter study of DDAVP versus platelet transfusions for antiplatelet agent reversal in patients with traumatic brain injury

Authors: Kristen M. Westfall, Jessica Andrews, Erin Sadek, William Curtiss III, Jason Hecht

Published in: Neurological Sciences

Login to get access

Abstract

Background

Antiplatelet agents have been shown to worsen outcomes following traumatic injury. Research on desmopressin (DDAVP) and platelet transfusion for antiplatelet reversal is limited. We aimed to evaluate the effect of these agents on patients taking pre-injury antiplatelet medications who experienced traumatic brain injury (TBI) after blunt trauma.

Methods

This is a retrospective cohort study of adult trauma patients from 2014 to 2021 on aspirin and/or a P2Y12 inhibitor. Patients were stratified into groups based on if they received DDAVP, platelets, both agents, or neither.

Results

Of 5525 included patients, 4696 (85.4%) were not reversed, 461 (8.4%) received platelets, 173 (3.1%) received DDAVP, and 172 (3.1%) received both reversals. There was no statistically significant difference in length of stay between, but patients who received platelets or both reversals were more likely to have hospital complications (p < 0.05), longer hospital length of stay (p < 0.001), and longer ICU length of stay (p < 0.001) compared to those who did not receive reversal. A subgroup analysis of patients with a head AIS of 4 or 5 confirmed these findings.

Conclusions

Patients who received platelets or both reversals had a longer length of hospital stay and length of ICU stay. It is difficult to recommend one treatment over another based on our results alone. Further studies are needed to help clarify the risks and benefits of reversal agents in this patient population.
Literature
1.
Centers for Disease Control and Prevention. Surveillance report of traumatic brain injury-related deaths by age group, sex, and mechanism of injury—United States, 2018 and 2019. 2022.
2.
Smith K, Weeks S (2012) The impact of pre-injury anticoagulation therapy in the older adult patient experiencing a traumatic brain injury: a systematic review. JBI Database Syst Rev Implement Rep 10(58):4610–4621CrossRef
3.
Batchelor J, Grayson A (2013) A meta-analysis to determine the effect of preinjury antiplatelet agents on mortality in patients with blunt head trauma. Br J Neurosurg 27(1):12–18CrossRefPubMed
4.
Ohm C, Mina A, Howells G, Bair H, Bendick P (2005) Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage. J Trauma 58(3):518–522CrossRefPubMed
5.
Nishijima DK, Offerman SR, Ballard DW, Vinson DR, Chettipally UK, Rauchwerger AS et al (2012) Immediate and delayed traumatic intracranial hemorrhage in patients with head trauma and pre-injury warfarin or clopidogrel use. Ann Emerg Med 59(6):460CrossRefPubMedPubMedCentral
6.
Cucher D, Harmon L, Myer B, Ngyuen A, Rankin T, Cook A et al (2021) Critical traumatic brain injury is associated with worse coagulopathy. J Trauma Acute Care Surg 91(2):331–335CrossRefPubMed
7.
Galvagro SM, Fox EE, Appana SN, Baraniuk S, Bosarge PL, Bulger EM et al (2017) Outcomes following concomitant traumatic brain injury and hemorrhagic shock: a secondary analysis from the PROPPR Trial. J Trauma Acute Care Surg 83(4):668–674CrossRef
8.
Pelaez CA, Spilman SK, Bell CT, Eastman DK, Sidwell RA (2019) Not all head injured patients on antiplatelet drugs need platelets: integrating platelet reactivity testing into platelet transfusion guidelines. Injury 50(1):73–78CrossRefPubMed
9.
Yorkgitis BK, Tatum DM, Taghavi S, Schroeppel TJ, Noorbakhsh MR, Philps FH et al (2022) Eastern Association for the Surgery of Trauma Multicenter Trial: comparison of pre-injury antithrombotic use and reversal strategies among severe traumatic brain injury patients. J Trauma Acute Care Surg 92(1):88–92CrossRefPubMed
10.
Li X, Sun Z, Zhao W, Zhang J, Chen J, Li Y et al (2013) Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage: clinical article. J Neurosurg 118(1):94–103CrossRefPubMed
11.
Baharoglu MI, Cordonnier C, Salman RAS, de Gans K, Koopman MM, Brand A et al (2016) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 387(10038):2605–2613CrossRefPubMed
12.
Nishijima DK, Zehtabchi S, Berrong J, Legome E (2012) Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review. J Trauma Acute Care Surg 72(6):1658–1663CrossRefPubMedPubMedCentral
13.
Barnett CL, Mladsi D, Vredenburg M, Aggarwal K (2018) Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ 21(8):827–834CrossRefPubMed
14.
Franchini M (2007) The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol 82(8):731–735CrossRefPubMed
15.
Mannucci PM (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90(7):2515–2521CrossRefPubMed
16.
Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E et al (2010) Management of bleeding following major trauma: an updated European guideline. Crit Care 14(2):1–29CrossRef
17.
Özal E, Kuralay E, Bingöl H, Cingöz F, Ceylan S, Tatar H (2002) Does tranexamic acid reduce desmopressin-induced hyperfibrinolysis? J Thorac Cardiovasc Surg 123(3):539–543CrossRefPubMed
18.
Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E et al (2008) Desmopressin reduces transfusion needs after surgery a meta-analysis of randomized clinical trials. Anesthesiology 109:1063–1076CrossRefPubMed
19.
Furay EJ, Daley MJ, Satarasinghe P, Lara S, Aydelotte JD, Teixeira PG et al (2020) Desmopressin is a transfusion sparing option to reverse platelet dysfunction in patients with severe traumatic brain injury. J Trauma Acute Care Surg 88(1):80–86CrossRefPubMed
20.
Barletta JF, Abdul-Rahman D, Hall ST, Mangram AJ, Dzandu JK, Frontera JA, et al. The role of desmopressin on hematoma expansion in patients with mild traumatic brain injury prescribed pre-injury antiplatelet medications. Neurocritical Care 2020 332 33(2):405–13.
21.
Andersen LK, Hvas A-M, Hvas CL (2021) Effect of desmopressin on platelet dysfunction during antiplatelet therapy: a systematic review. Neurocrit Care 34:1026–1046CrossRefPubMed
22.
Sizemore S, Patel MVB, Carter B, Garrett E (2022) Adjusting vasopressin availability and formulation: a cost-savings initiative. Am J Health Syst Pharm 79(Suppl 3):S74–S78CrossRefPubMed
23.
Pandya U, Malik A, Messina M, Albeiruti AR, Spalding C (2018) Reversal of antiplatelet therapy in traumatic intracranial hemorrhage: does timing matter? J Clin Neurosci 1(50):88–92CrossRef
24.
Joseph B, Pandit V, Aziz H, Kulvatunyou N, Hashmi A, Tang A et al (2014) Clinical outcomes in traumatic brain injury patients on preinjury clopidogrel: a prospective analysis. J Trauma Acute Care Surg 76(3):817–820CrossRefPubMed
Metadata
Title
A multicenter study of DDAVP versus platelet transfusions for antiplatelet agent reversal in patients with traumatic brain injury
Authors
Kristen M. Westfall
Jessica Andrews
Erin Sadek
William Curtiss III
Jason Hecht
Publication date
14-02-2024
Publisher
Springer International Publishing
Published in
Neurological Sciences
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-024-07379-x